Table 1.
Demographic characteristics, N = 30
Participants, N (%) | |
---|---|
Age (years)a | 52 (46–59) |
Race | |
Hispanic | 22 (73) |
African American | 4 (13) |
Others | 4 (13) |
HIV-HCV co-infection | 7 (23) |
HCV treatmentb | 22 (73) |
aGiven as median (IQR)
bTreatment administered as pegylated IFN and ribavirin; eight separate participants received pegylated IFN, telaprevir, and ribavirin